_id
695fb5edc2e91020a7bd41ec
Ticker
0HB0.LSE
Name
Agios Pharmaceuticals, Inc.
Exchange
LSE
Address
88 Sidney Street, Cambridge, MA, United States, 02139
Country
UK
Sector
Industry
Currency
USD
Website
https://www.agios.com
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Last Close
27.47
Volume
100
Current Price
28.5007
Last Updated
2026-01-08T13:49:33.525Z
Ipo Date
-
Market Cap
124089177600
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
12880000
Cost Of Revenue
1679000
Gross Profit
11201000
Operating Expenses
128070000
Operating Income
-116869000
Interest Expense
-
Pretax Income
-103433000
Net Income
-103433000
Eps
-1.7790554911785366
Dividends Per Share
-
Shares Outstanding
58178700
Income Tax Expense
-
EBITDA
-102059000
Operating Margin
-907.3680124223604
Total Other Income Expense Net
13436000
Cash
92710000
Short Term Investments
860150000
Receivables
5029000
Inventories
32034000
Total Current Assets
1033109000
Property Plant Equipment
44325000
Total Assets
1385705000
Payables
19553000
Short Term Debt
17987000
Long Term Debt
-
Total Liabilities
101375000
Equity
1284330000
Bs_currency_symbol
-
Depreciation
1374000
Change In Working Capital
-231000
Cash From Operations
-88151000
Capital Expenditures
1555000
Cash From Investing
95555000
Cash From Financing
4435000
Net Change In Cash
11839000
Cf_currency_symbol
-
PE
-
PB
1.2901747152164165
ROE
-8.053459780585987
ROA
-7.464287131820986
FCF
-89706000
Fcf Percent
-6.964751552795031
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
4.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
12880000
Quarters > 0 > income Statement > cost Of Revenue
1679000
Quarters > 0 > income Statement > gross Profit
11201000
Quarters > 0 > income Statement > operating Expenses
128070000
Quarters > 0 > income Statement > operating Income
-116869000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-103433000
Quarters > 0 > income Statement > net Income
-103433000
Quarters > 0 > income Statement > eps
-1.7790554911785366
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
58139277
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-102059000
Quarters > 0 > income Statement > operating Margin
-907.3680124223604
Quarters > 0 > income Statement > total Other Income Expense Net
13436000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
92710000
Quarters > 0 > balance Sheet > short Term Investments
860150000
Quarters > 0 > balance Sheet > receivables
5029000
Quarters > 0 > balance Sheet > inventories
32034000
Quarters > 0 > balance Sheet > total Current Assets
1033109000
Quarters > 0 > balance Sheet > property Plant Equipment
44325000
Quarters > 0 > balance Sheet > total Assets
1385705000
Quarters > 0 > balance Sheet > payables
19553000
Quarters > 0 > balance Sheet > short Term Debt
17987000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
101375000
Quarters > 0 > balance Sheet > equity
1284330000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-103433000
Quarters > 0 > cash Flow > depreciation
1374000
Quarters > 0 > cash Flow > change In Working Capital
-231000
Quarters > 0 > cash Flow > cash From Operations
-88151000
Quarters > 0 > cash Flow > capital Expenditures
1555000
Quarters > 0 > cash Flow > cash From Investing
95555000
Quarters > 0 > cash Flow > cash From Financing
4435000
Quarters > 0 > cash Flow > net Change In Cash
11839000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-1.7790554911785366
Quarters > 0 > ratios > PB
1.2901747152164165
Quarters > 0 > ratios > ROE
-8.053459780585987
Quarters > 0 > ratios > ROA
-7.464287131820986
Quarters > 0 > ratios > FCF
-89706000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-6.964751552795031
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
12455000
Quarters > 1 > income Statement > cost Of Revenue
2961000
Quarters > 1 > income Statement > gross Profit
9494000
Quarters > 1 > income Statement > operating Expenses
136550000
Quarters > 1 > income Statement > operating Income
-127056000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-112020000
Quarters > 1 > income Statement > net Income
-112020000
Quarters > 1 > income Statement > eps
-1.9336271185317222
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
57932576
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-110761000
Quarters > 1 > income Statement > operating Margin
-1020.1204335608189
Quarters > 1 > income Statement > total Other Income Expense Net
15036000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
80871000
Quarters > 1 > balance Sheet > short Term Investments
858066000
Quarters > 1 > balance Sheet > receivables
4986000
Quarters > 1 > balance Sheet > inventories
30848000
Quarters > 1 > balance Sheet > total Current Assets
1019464000
Quarters > 1 > balance Sheet > property Plant Equipment
47364000
Quarters > 1 > balance Sheet > total Assets
1471237000
Quarters > 1 > balance Sheet > payables
17532000
Quarters > 1 > balance Sheet > short Term Debt
17589000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
101682000
Quarters > 1 > balance Sheet > equity
1369555000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
-112020000
Quarters > 1 > cash Flow > depreciation
1259000
Quarters > 1 > cash Flow > change In Working Capital
8284000
Quarters > 1 > cash Flow > cash From Operations
-77124000
Quarters > 1 > cash Flow > capital Expenditures
875000
Quarters > 1 > cash Flow > cash From Investing
78966000
Quarters > 1 > cash Flow > cash From Financing
65000
Quarters > 1 > cash Flow > net Change In Cash
1907000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.9336271185317222
Quarters > 1 > ratios > PB
1.2055879236709732
Quarters > 1 > ratios > ROE
-8.1792991154061
Quarters > 1 > ratios > ROA
-7.614001007315613
Quarters > 1 > ratios > FCF
-77999000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-6.2624648735447614
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
8726000
Quarters > 2 > income Statement > cost Of Revenue
73828000
Quarters > 2 > income Statement > gross Profit
-65102000
Quarters > 2 > income Statement > operating Expenses
41527000
Quarters > 2 > income Statement > operating Income
-106629000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-89289000
Quarters > 2 > income Statement > net Income
-89289000
Quarters > 2 > income Statement > eps
-1.553954941415382
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
57459195
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-105351000
Quarters > 2 > income Statement > operating Margin
-1221.9688287875315
Quarters > 2 > income Statement > total Other Income Expense Net
17340000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
78964000
Quarters > 2 > balance Sheet > short Term Investments
814411000
Quarters > 2 > balance Sheet > receivables
3344000
Quarters > 2 > balance Sheet > inventories
29605000
Quarters > 2 > balance Sheet > total Current Assets
968616000
Quarters > 2 > balance Sheet > property Plant Equipment
50928000
Quarters > 2 > balance Sheet > total Assets
1555518000
Quarters > 2 > balance Sheet > payables
13726000
Quarters > 2 > balance Sheet > short Term Debt
34392000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
88990000
Quarters > 2 > balance Sheet > equity
1466528000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
-89289000
Quarters > 2 > cash Flow > depreciation
1278000
Quarters > 2 > cash Flow > change In Working Capital
-33496000
Quarters > 2 > cash Flow > cash From Operations
-111489000
Quarters > 2 > cash Flow > capital Expenditures
766000
Quarters > 2 > cash Flow > cash From Investing
112587000
Quarters > 2 > cash Flow > cash From Financing
1619000
Quarters > 2 > cash Flow > net Change In Cash
2717000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-1.553954941415382
Quarters > 2 > ratios > PB
1.116669629858073
Quarters > 2 > ratios > ROE
-6.0884620000436405
Quarters > 2 > ratios > ROA
-5.740145726375394
Quarters > 2 > ratios > FCF
-112255000
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-12.864428145771258
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
10730000
Quarters > 3 > income Statement > cost Of Revenue
2627000
Quarters > 3 > income Statement > gross Profit
8103000
Quarters > 3 > income Statement > operating Expenses
133140000
Quarters > 3 > income Statement > operating Income
-125037000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-105399000
Quarters > 3 > income Statement > net Income
-96523000
Quarters > 3 > income Statement > eps
-1.6887556635285166
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
57156285
Quarters > 3 > income Statement > income Tax Expense
-8876000
Quarters > 3 > income Statement > EBITDA
-104032000
Quarters > 3 > income Statement > operating Margin
-1165.3028890959924
Quarters > 3 > income Statement > total Other Income Expense Net
19638000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
76247000
Quarters > 3 > balance Sheet > short Term Investments
817463000
Quarters > 3 > balance Sheet > receivables
4109000
Quarters > 3 > balance Sheet > inventories
27616000
Quarters > 3 > balance Sheet > total Current Assets
965600000
Quarters > 3 > balance Sheet > property Plant Equipment
54554000
Quarters > 3 > balance Sheet > total Assets
1663199000
Quarters > 3 > balance Sheet > payables
16643000
Quarters > 3 > balance Sheet > short Term Debt
16781000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
122243000
Quarters > 3 > balance Sheet > equity
1540956000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-96523000
Quarters > 3 > cash Flow > depreciation
1367000
Quarters > 3 > cash Flow > change In Working Capital
-46261000
Quarters > 3 > cash Flow > cash From Operations
-133167000
Quarters > 3 > cash Flow > capital Expenditures
967000
Quarters > 3 > cash Flow > cash From Investing
-49158000
Quarters > 3 > cash Flow > cash From Financing
4842000
Quarters > 3 > cash Flow > net Change In Cash
-177483000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.6887556635285166
Quarters > 3 > ratios > PB
1.057132151663967
Quarters > 3 > ratios > ROE
-6.263838811750627
Quarters > 3 > ratios > ROA
-5.803454667781787
Quarters > 3 > ratios > FCF
-134134000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-12.500838769804288
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
36498000
Annuals > 0 > income Statement > cost Of Revenue
9818000
Annuals > 0 > income Statement > gross Profit
26680000
Annuals > 0 > income Statement > operating Expenses
452417000
Annuals > 0 > income Statement > operating Income
-425737000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
717969000
Annuals > 0 > income Statement > net Income
673725000
Annuals > 0 > income Statement > eps
11.638170157829808
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
57889255
Annuals > 0 > income Statement > income Tax Expense
44244000
Annuals > 0 > income Statement > EBITDA
723622000
Annuals > 0 > income Statement > operating Margin
-1166.4666557071619
Annuals > 0 > income Statement > total Other Income Expense Net
1143706000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
76247000
Annuals > 0 > balance Sheet > short Term Investments
817463000
Annuals > 0 > balance Sheet > receivables
4109000
Annuals > 0 > balance Sheet > inventories
27616000
Annuals > 0 > balance Sheet > total Current Assets
965600000
Annuals > 0 > balance Sheet > property Plant Equipment
54554000
Annuals > 0 > balance Sheet > total Assets
1663199000
Annuals > 0 > balance Sheet > payables
16643000
Annuals > 0 > balance Sheet > short Term Debt
16781000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
122243000
Annuals > 0 > balance Sheet > equity
1540956000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
673725000
Annuals > 0 > cash Flow > depreciation
5653000
Annuals > 0 > cash Flow > change In Working Capital
-19768000
Annuals > 0 > cash Flow > cash From Operations
-389841000
Annuals > 0 > cash Flow > capital Expenditures
1685000
Annuals > 0 > cash Flow > cash From Investing
363441000
Annuals > 0 > cash Flow > cash From Financing
14442000
Annuals > 0 > cash Flow > net Change In Cash
-11958000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
11.638170157829808
Annuals > 0 > ratios > PB
1.0706887737083344
Annuals > 0 > ratios > ROE
43.72123538894037
Annuals > 0 > ratios > ROA
40.507780488083505
Annuals > 0 > ratios > FCF
-391526000
Annuals > 0 > ratios > Piotroski FScore
2
Annuals > 0 > ratios > fcf Percent
-10.727327524795879
Annuals > 0 > health Score
71
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
26823000
Annuals > 1 > income Statement > cost Of Revenue
9504000
Annuals > 1 > income Statement > gross Profit
17319000
Annuals > 1 > income Statement > operating Expenses
408806000
Annuals > 1 > income Statement > operating Income
-391487000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-352088000
Annuals > 1 > income Statement > net Income
-352088000
Annuals > 1 > income Statement > eps
-6.326659339758523
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
55651487
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-345465000
Annuals > 1 > income Statement > operating Margin
-1459.5198150840697
Annuals > 1 > income Statement > total Other Income Expense Net
39399000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
88205000
Annuals > 1 > balance Sheet > short Term Investments
688723000
Annuals > 1 > balance Sheet > receivables
2810000
Annuals > 1 > balance Sheet > inventories
19076000
Annuals > 1 > balance Sheet > total Current Assets
833835000
Annuals > 1 > balance Sheet > property Plant Equipment
69791000
Annuals > 1 > balance Sheet > total Assets
937118000
Annuals > 1 > balance Sheet > payables
9780000
Annuals > 1 > balance Sheet > short Term Debt
15008000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
126099000
Annuals > 1 > balance Sheet > equity
811019000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-352088000
Annuals > 1 > cash Flow > depreciation
6623000
Annuals > 1 > cash Flow > change In Working Capital
-10324000
Annuals > 1 > cash Flow > cash From Operations
-296062000
Annuals > 1 > cash Flow > capital Expenditures
999000
Annuals > 1 > cash Flow > cash From Investing
239575000
Annuals > 1 > cash Flow > cash From Financing
5433000
Annuals > 1 > cash Flow > net Change In Cash
-51054000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-6.326659339758523
Annuals > 1 > ratios > PB
1.9556956563790737
Annuals > 1 > ratios > ROE
-43.4130396451871
Annuals > 1 > ratios > ROA
-37.57136241113713
Annuals > 1 > ratios > FCF
-297061000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-11.074861126645043
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
14240000
Annuals > 2 > income Statement > cost Of Revenue
20263000
Annuals > 2 > income Statement > gross Profit
-6023000
Annuals > 2 > income Statement > operating Expenses
383024000
Annuals > 2 > income Statement > operating Income
-389047000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-231801000
Annuals > 2 > income Statement > net Income
-231801000
Annuals > 2 > income Statement > eps
-4.230760912208713
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
54789435
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-213242000
Annuals > 2 > income Statement > operating Margin
-2732.0716292134834
Annuals > 2 > income Statement > total Other Income Expense Net
157246000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
139259000
Annuals > 2 > balance Sheet > short Term Investments
643860000
Annuals > 2 > balance Sheet > receivables
2206000
Annuals > 2 > balance Sheet > inventories
8492000
Annuals > 2 > balance Sheet > total Current Assets
832772000
Annuals > 2 > balance Sheet > property Plant Equipment
88116000
Annuals > 2 > balance Sheet > total Assets
1238718000
Annuals > 2 > balance Sheet > payables
18616000
Annuals > 2 > balance Sheet > short Term Debt
13663000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
137904000
Annuals > 2 > balance Sheet > equity
1100814000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-231801000
Annuals > 2 > cash Flow > depreciation
8564000
Annuals > 2 > cash Flow > change In Working Capital
-16433000
Annuals > 2 > cash Flow > cash From Operations
-309478000
Annuals > 2 > cash Flow > capital Expenditures
4881000
Annuals > 2 > cash Flow > cash From Investing
243261000
Annuals > 2 > cash Flow > cash From Financing
2350000
Annuals > 2 > cash Flow > net Change In Cash
-63867000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-4.230760912208713
Annuals > 2 > ratios > PB
1.4185296063681059
Annuals > 2 > ratios > ROE
-21.057235827305977
Annuals > 2 > ratios > ROA
-18.71297583469361
Annuals > 2 > ratios > FCF
-314359000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-22.075772471910113
Annuals > 2 > health Score
35
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
18777000
Annuals > 3 > income Statement > gross Profit
-18777000
Annuals > 3 > income Statement > operating Expenses
359641000
Annuals > 3 > income Statement > operating Income
-378418000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-356510000
Annuals > 3 > income Statement > net Income
-384418000
Annuals > 3 > income Statement > eps
-6.359551335802237
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
60447346
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-337733000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
21908000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
203126000
Annuals > 3 > balance Sheet > short Term Investments
816892000
Annuals > 3 > balance Sheet > receivables
4378000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
1064231000
Annuals > 3 > balance Sheet > property Plant Equipment
104230000
Annuals > 3 > balance Sheet > total Assets
1437736000
Annuals > 3 > balance Sheet > payables
16700000
Annuals > 3 > balance Sheet > short Term Debt
11159000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
145761000
Annuals > 3 > balance Sheet > equity
1291975000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-356510000
Annuals > 3 > cash Flow > depreciation
18777000
Annuals > 3 > cash Flow > change In Working Capital
-36822000
Annuals > 3 > cash Flow > cash From Operations
-407320000
Annuals > 3 > cash Flow > capital Expenditures
5741000
Annuals > 3 > cash Flow > cash From Investing
1248778000
Annuals > 3 > cash Flow > cash From Financing
-765768000
Annuals > 3 > cash Flow > net Change In Cash
75690000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-6.359551335802237
Annuals > 3 > ratios > PB
1.33345589051042
Annuals > 3 > ratios > ROE
-29.754290911201842
Annuals > 3 > ratios > ROA
-26.7377321010255
Annuals > 3 > ratios > FCF
-413061000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
43
Valuation > metrics > PE
-1.7790554911785366
Valuation > metrics > PB
1.2901747152164165
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-8.053459780585987
Profitability > metrics > ROA
-10.011818694832781
Profitability > metrics > Net Margin
-8.030512422360248
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.07893220589723825
Risk > metrics > Interest Coverage
-85.05749636098982
Risk > final Score
-280
Risk > verdict
High
Liquidity > metrics > Current Ratio
27.520218433670752
Liquidity > metrics > Quick Ratio
26.666888652104422
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-344
Prev Risks > 1
33
Prev Risks > 2
-306
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:27.326Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-12
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-1.95
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Agios Pharmaceuticals, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-1.95
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.